Cat.No. | Name | Information |
---|---|---|
M4084 | Ginsenoside-F2 | Ginsenoside F2, a metabolite of Ginsenoside Rb1, induces apoptosis and protective autophagy in breast cancer stem cells. |
M4083 | Ginsenoside-F1 | Ginsenoside F1 is an enzymatically modified derivative of Ginsenoside Rg1. Ginsenoside F1 competently inhibits CYP3A4 and has a weak inhibitory effect on CYP2D6. |
M4082 | Protopanaxtriol | 20(R)-Protopanaxatriol is a natural ginsenoside ligand of Re, Rf, Rg1, Rg2 and Rh. |
M4081 | (R)Ginsenoside-Rg3 | (20R) -Ginsenoside Rg3 ((20R)-Propanaxadiol), an active compound from ginseng root, has inhibitory effects on vascular endothelial cell proliferation (IC50= 10 nM) and antitumor activity. |
M4080 | (R)Ginsenoside-Rg2 | 20(R) -ginsenoside Rg2 is a Ginsenoside. 20(R)-Ginsenoside Rg2 has an inhibitory effect on lung cancer NCI-H1650 cells. It has anti-cancer activity. |
M4079 | (R)Ginsenoside-Rh2 | 20(R)-Ginsenoside Rh2, a matrix metalloproteinase (MMP) inhibitor, acts as an anti-proliferative agent in cells. It has anticancer effects by blocking cell proliferation and causing G1 phase arrest. 20(R)-Ginsenoside Rh2 induces apoptosis and has anti-inflammatory and antioxidant activities. 20(R)-Ginsenoside Rh2 inhibited the replication and proliferation of mouse and human γ herpevirus 68 (MHV-68) with an IC50 of 2.77 μM against mouse MHV-68. |
M4078 | (R)Ginsenoside-Rh1 | (R)Ginsenoside-Rh1 is one of the important protopanaxatriol ginsenosides and has been reported to be the main hydrolysis product reaching the systemic circulation after oral ingestion of ginseng. |
M4077 | Pseudoginsenoside-RT5 | Pseudoginsenoside RT5 was isolated from Panax quinquefolium. |
M4076 | Ginsenoside-Rf | Ginsenoside Rf is a trace component of ginseng root. Ginsenoside Rf inhibits N-type Ca2+ channels. |
M4075 | Ginsenoside-Rd | Ginsenoside Rd inhibited NF-κB transcriptional activity induced by TNFα with IC50 of 12.05±0.82 μM. Ginsenoside Rd inhibited the expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca2+ influx. Ginsenoside Rd inhibited CYP2D6, CYP1A2, CYP3A4 and CYP2C9 with IC50 of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM and 85.1±9.1 μM, respectively. |
M4074 | Ginsenoside-Re | Ginsenoside Re (Ginsenoside B2) is a ginseng - ginseng extract. Ginsenoside Re reduces beta-amyloid (Aβ). Ginsenoside Re also exerts anti-inflammatory effects by inhibiting JNK and NF-κB. |
M4073 | Ginsenoside-Rc | Ginsenoside Rc is one of the major ginsenosides. Ginsenoside Rc enhances GABA receptor A (GABAA) -mediated ion channel (IGABA) currents. Ginsenoside Rc also inhibited TNF-α and IL-1β expression. |
M4072 | Ginsenoside-Rh3 | Ginsenoside Rh3 is a bacterial metabolite of Ginsenoside Rg5. Ginsenoside Rh3 induces Nrf2 activation in human retinal cells. |
M4071 | Pseudoginsenoside-Rh2 | Pseudoginsenoside Rh2 is synthesized by Ginsenoside Rh2 and has antitumor activity. |
M4070 | (S)Ginsenoside-Rh2 | (S)Ginsenoside-Rh2 is isolated from the root of Ginseng, induces the activation of caspase-8 and caspase-9. |
M4069 | (S)Ginsenoside-Rh1 | Ginsenoside Rh1 (Prosapogenin A2) inhibited the expression of PPAR-γ, TNF-α, IL-6 and IL-1β. |
M4068 | Ginsenoside-Rg3 | 20(S)-Ginsenoside Rg3 is the main ingredient of red ginseng. 20(S) -ginsenoside Rg3 inhibited Na+ and hKv1.4 channels with IC50 of 32.2±4.5 and 32.6±2.2 μM, respectively. 20(S) -ginsenoside Rg3 also inhibited Aβ, NF-κB activity and COX-2 expression. |
M4067 | Ginsenoside-Rg2 | Ginsenoside-Rg2 is one of the major active components of ginseng, acts as a NF-κB inhibitor. |
M4066 | Ginsenoside-Rb3 | Ginsenoside Rb3 is derived from Panax Notoginseng. Ginsenoside Rb3 inhibited NF-κB transcriptional activity induced by TNFα in 293T cell lines with IC50 of 8.2 μM. Ginsenoside Rb3 also inhibited the induction of COX-2 and iNOS mRNA. |
M4065 | Ginsenoside-Rb2 | Ginsenoside Rb2 is one of the main bioactive components of ginseng extract. Ginsenoside Rb2 can up-regulate GPR120 gene expression. Ginsenoside Rb2 has antiviral effects. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.